Filla A, De Michele G, Orefice G, Santorelli F, Trombetta L, Banfi S, Squitieri F, Napolitano G, Puma D, Campanella G
Department of Neurology, Second School of Medicine, Federico II University, Naples, Italy.
Can J Neurol Sci. 1993 Feb;20(1):52-5. doi: 10.1017/s0317167100047417.
We performed a double-blind cross-over study with amantadine hydrochloride in 12 patients with Friedreich's disease and 2 with autosomal dominant cerebellar ataxia. Patients were randomly assigned to a placebo-amantadine or amantadine-placebo sequence. The interval between the treatments was two weeks. Patients were graded according to a functional ataxia scoring scale and videotaped in basal conditions and 90 min after a single oral dose of 100 mg amantadine or placebo. Three evaluators independently scored the videotapes. Statistical analysis showed no significant effect of amantadine in Friedreich's disease.
我们对12例弗里德赖希共济失调患者和2例常染色体显性遗传性小脑共济失调患者进行了盐酸金刚烷胺双盲交叉研究。患者被随机分配接受安慰剂 - 金刚烷胺或金刚烷胺 - 安慰剂序列治疗。治疗间隔为两周。根据功能性共济失调评分量表对患者进行分级，并在基础状态以及单次口服100mg金刚烷胺或安慰剂90分钟后进行录像。三名评估人员独立对录像进行评分。统计分析表明，金刚烷胺对弗里德赖希共济失调无显著疗效。
